DNLI - Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

2024-05-13 12:30:16 ET

Summary

• Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024.
• Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II.
• Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024.
• Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis.

Denali Therapeutics Inc. ( DNLI ) is advancing a drug by the name of DNL-310 [tividenofusp alfa] for the treatment of patients with MSP II [Hunter Syndrome]. It had been able to report positive results from an ongoing phase 1/2 study, using this drug to treat these patients, at the 20th Annual WORLD Symposium....

For further details see: